INNOGEN-B (02591) Completes First Patient Dosing in China for Phase III Clinical Trial of Core Product Isupaglutide α for Obesity and Overweight Treatment

Stock News
Yesterday

INNOGEN-B (02591) announced that on September 30, 2025, the company has completed the first patient dosing in China for the Phase III clinical trial of its core product, isupaglutide α, for the treatment of obesity and overweight conditions. The company plans to recruit approximately 800 participants for this clinical trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10